Pharyngoconjunctival Fever Medication
- Author: Ingrid U Scott, MD, MPH; Chief Editor: Hampton Roy Sr, MD more...
Medication Summary
Medications currently used in the treatment of PCF include the following: topical artificial tears 4-8 times per day for 1-3 weeks, topical vasoconstrictor/antihistamine 4 times per day for severe itching, topical steroids for pseudomembranes and subepithelial infiltrates, and topical antibiotic to prevent bacterial superinfection.[5, 6]
Ocular lubricants
Class Summary
Used for symptomatic relief.
Artificial tears (Celluvisc, Murine, Artificial Tears, Tears Naturale, Refresh)
Acts to stabilize and thicken precorneal tear film and prolong tear film breakup time, which occurs with dry eye states. Preservative-free tear preparations may be particularly appropriate.
Antihistamines
Class Summary
For severe itching; these include first-generation antihistamines prescribed over the counter (eg, naphazoline), second-generation therapy with agents (eg, levocabastine [Livostin], lodoxamide [Alomide]), and third-generation drugs (eg, olopatadine [Patanol], nedocromil [Alocril], pemirolast [Alamast], ketotifen [Zaditor]). Third-generation drugs may have antihistamine, mast cell stabilizing, and cell-mediated immunity inhibitory effects.
Levocabastine (Livostin)
Potent histamine H1-receptor antagonist, for ophthalmic use.
Corticosteroids
Class Summary
Have anti-inflammatory properties and cause profound and varied metabolic effects. Corticosteroids modify the body's immune response to diverse stimuli. For pseudomembranes and subepithelial infiltrates, which cause glare and/or decreased vision.
Prednisolone ophthalmic (AK-Pred, Pred Forte)
Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability.
In cases of bacterial infections, concomitant use of anti-infective agents is mandatory; if signs and symptoms do not improve after 2 days, reevaluate patient. Dosing may be reduced, but advise patients not to discontinue therapy prematurely.
Loteprednol etabonate (Lotemax, Alrex)
Unique retromolecular engineering design ester steroid is metabolized rapidly when unbound to glucocorticoid receptor. Decreased incidence of significant intraocular pressure elevations in FDA study protocols. Efficacy similar to dexamethasone and prednisolone.
Nonsteroidal anti-inflammatory agents (NSAIDs)
Class Summary
Have analgesic, anti-inflammatory, and antipyretic activities. Their mechanism of action is not known but may inhibit cyclooxygenase activity and prostaglandin synthesis. Other mechanisms may exist as well, such as inhibition of leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell membrane functions.
Diclofenac ophthalmic (Voltaren)
Inhibits prostaglandin synthesis by decreasing activity of enzyme cyclooxygenase, which, in turn, decreases formation of prostaglandin precursors.
Ketorolac ophthalmic (Acular)
Potent prostaglandin inhibitor. Acular also is available in a preservative-free single-dose unit preparation at additional cost. Formulation is extremely useful in patients with ocular surface disease, including adenovirus infection, as well as in the perioperative period.
Melendez CP, Florentino MM, Martinez IL, Lopez HM. Outbreak of epidemic keratoconjunctivitis caused by adenovirus in medical residents. Mol Vis. 2009;15:557-62. [Medline].
Dosso AA, Rungger-Brändle E. Clinical course of epidemic keratoconjunctivitis: evaluation by in vivo confocal microscopy. Cornea. Apr 2008;27(3):263-8. [Medline].
Ishiko H, Aoki K. Spread of epidemic keratoconjunctivitis due to a novel serotype of human adenovirus in Japan. J Clin Microbiol. May 6 2009;[Medline].
Artieda J, Pineiro L, Gonzalez M, Munoz M, Basterrechea M, Iturzaeta A, et al. A swimming pool-related outbreak of pharyngoconjunctival fever in children due to adenovirus type 4, Gipuzkoa, Spain, 2008. Euro Surveill. Feb 26 2009;14(8):[Medline].
Monnerat N, Bossart W, Thiel MA. [Povidone-iodine for treatment of adenoviral conjunctivitis: an in vitro study]. Klin Monatsbl Augenheilkd. May 2006;223(5):349-52. [Medline].
Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. May-Jun 2009;54(3):321-38. [Medline].
Chang CH, Lin KH, Sheu MM, et al. The change of etiological agents and clinical signs of epidemic viral conjunctivitis over an 18-year period in southern Taiwan. Graefes Arch Clin Exp Ophthalmol. Jul 2003;241(7):554-60. [Medline].
D'Angelo LJ, Hierholzer JC, Keenlyside RA, et al. Pharyngoconjunctival fever caused by adenovirus type 4: report of a swimming pool-related outbreak with recovery of virus from pool water. J Infect Dis. Jul 1979;140(1):42-7. [Medline].
Dawson CR, Sheppard JD. Follicular conjunctivitis In: Duane TA and Jaeger EW, eds. Duane's Clinical Ophthalmology. Vol. 4. 1989.
Diamante GG, Leibowitz HM. Superficial punctate keratopathy. In: Leibowitz HM and Waring GO, eds. Corneal Disorders: Diagnosis and Management. 2nd ed. 1998:432-479.
Liesegang TJ. Conjunctiva. In: Wright KW, ed. Textbook of Ophthalmology. 1997;665-690.
McMillan NS, Martin SA, Sobsey MD, et al. Outbreak of pharyngoconjunctival fever at a summer camp -- North Carolina, 1991. JAMA. 1992;267:2867-2868.
Nakayama M, Miyazaki C, Ueda K, et al. Pharyngoconjunctival fever caused by adenovirus type 11. Pediatr Infect Dis J. Jan 1992;11(1):6-9. [Medline].
Pavan-Langston D. Viral diseases of the cornea and external eye. In: Albert DM, Jakobiec FA, eds. Principles and Practices of Ophthalmology. Vol. 1. 1994:117-161.
Reed DB. Viral and bacterial conjunctivitis. Prevention of disastrous results. Postgrad Med. Sep 15 1989;86(4):103-4, 107-9, 113-4. [Medline].
Rietveld RP, van Weert HC, ter Riet G, Bindels PJ. Diagnostic impact of signs and symptoms in acute infectious conjunctivitis: systematic literature search. BMJ. Oct 4 2003;327(7418):789. [Medline].
Syed NA, Hyndiuk RA. Infectious conjunctivitis. Infect Dis Clin North Am. Dec 1992;6(4):789-805. [Medline].
van Bijsterveld OP, de Jong JC, Muzerie CJ, Wermenbol AG. Pharyngoconjunctival fever caused by adenovirus type 19. Ophthalmologica. 1978;177(3):134-9. [Medline].
Print
